Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4634 Comments
1497 Likes
1
Xyaire
Active Contributor
2 hours ago
Pure excellence, served on a silver platter. 🍽️
👍 225
Reply
2
Phonesavanh
Legendary User
5 hours ago
My mind just did a backflip. 🤸♂️
👍 137
Reply
3
Muawiyah
Returning User
1 day ago
As someone busy with work, I just missed it.
👍 10
Reply
4
Alexiz
Legendary User
1 day ago
I understood everything for 0.3 seconds.
👍 93
Reply
5
Kollins
Daily Reader
2 days ago
I read this and now I’m thinking in circles.
👍 77
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.